Nothing Special   »   [go: up one dir, main page]

HRP20220581T1 - Spojevi korisni kao inhibitori atr kinaze - Google Patents

Spojevi korisni kao inhibitori atr kinaze Download PDF

Info

Publication number
HRP20220581T1
HRP20220581T1 HRP20220581TT HRP20220581T HRP20220581T1 HR P20220581 T1 HRP20220581 T1 HR P20220581T1 HR P20220581T T HRP20220581T T HR P20220581TT HR P20220581 T HRP20220581 T HR P20220581T HR P20220581 T1 HRP20220581 T1 HR P20220581T1
Authority
HR
Croatia
Prior art keywords
4alkyl
image
alkyl
4aliphatic
optionally substituted
Prior art date
Application number
HRP20220581TT
Other languages
English (en)
Inventor
Jean-Damien Charrier
Steven Durrant
David Kay
Ronald Knegtel
Somhairle Maccormick
Michael Mortimore
Michael O'donnell
Joanne Pinder
Alistair Rutherford
Anisa Nizarali Virani
Stephen Young
Philip Michael Reaper
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of HRP20220581T1 publication Critical patent/HRP20220581T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S507/00—Earth boring, well treating, and oil field chemistry
    • Y10S507/939—Corrosion inhibitor

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Claims (22)

1. Spoj formule IA: [image] ili njegova farmaceutski prihvatljiva sol; naznačen time, da Y je C1-C10alifatski lanac u kojem su po izboru zamijenjene do tri metilenske jedinice alifatskog lanca s O, NR0, S, C(O) ili S(O)2; Prsten A je heteroarilni prsten s 5 članova odabran između [image] J3 je H ili C1-4alkil pri čemu 1 metilenska jedinica alkilne skupine može po izboru biti zamijenjena s O, NH, N(C1-4alkil), ili S i po izboru supstituirana s 1 do 3 halo; Q je monociklički aromatski prsten s 5 do 6 članova koji sadržava 0 do 4 heteroatoma neovisno odabrana između dušika, kisika ili sumpora; ili biciklički aromatski prsten s 8 do 10 članova koji sadržava 0 do 6 heteroatoma neovisno odabrana između dušika, kisika ili sumpora; R5 je H; monociklički potpuno zasićeni, djelomično nezasićeni ili aromatski prsten s 3 do 7 članova koji sadržava 0 do 4 heteroatoma neovisno odabrana između dušika, kisika ili sumpora; biciklički potpuno zasićeni, djelomično nezasićeni ili aromatski prsten s 8 do 10 članova koji sadržava 0 do 6 heteroatoma neovisno odabrana između dušika, kisika, ili sumpora; R5 je po izboru supstituiran s 1 do 5 J5 skupina; L je C1-4alkil lanac u kojem su-dvije metilenske jedinice alkilnog lanca po izboru zamijenjene s O, NR6, S, -C(O)-, -SO- ili -SO2-; R0 je H ili C1-C6alkil pri čemu se jedna metilenska jedinica alkilnog lanca može po izboru zamijeniti s O, NH, N(C1-4alkil), ili S; R1 je H ili C1-C6alkil; R2 je H, C1-C6alkil, -(C2-C6alkil)-Z ili ciklički prsten s 4 do 8 članova koji sadržava 0 do 2 atoma dušika; pri čemu je navedeni prsten vezan preko ugljikovog atoma i po izboru je supstituiran s jednom pojavom JZ; ili R1 i R2, zajedno s atomom na koji su vezani, tvore heterociklički prsten s 4 do 8 članova koji sadržava 1 do 2 heteroatoma odabrana između kisika, dušika ili sumpora; pri čemu je navedeni heterociklički prsten po izboru zamijenjen s jednim pojavljivanjem JZ1; JZ1 je halo, CN, C1-C8alifat, -(X)t-CN ili -(X)R-Z; pri čemu se navedene-dvije metilenske jedinice navedenog C1-C8alifata mogu po izboru zamijeniti s O, NR, S, P(O), C(O), S(O) ili S(O)2; pri čemu je navedeni C1-C8alifat po izboru supstituiran s halo, CN ili NO2; X je C1-C4alkil; svaki t, r i m je neovisno 0 ili 1; Z je -NR3R4; R3 je H ili C1-C2alkil; R4 je H ili C1-C6 alkil; ili R3 i R4, zajedno s atomom na koji su vezani, tvore heterociklički prsten s 4 do 8 članova koji sadržava 1 do 2 heteroatoma odabrana između kisika, dušika ili sumpora; pri čemu je navedeni prsten po izboru supstituiran s jednom pojavom JZ; R6 je H, ili C1-C6alkil; JZ je neovisno NH2, NH(C1-4alifat), N(C1-4alifat)2, halogen, C1-4alifat, OH, O(C1-4alifat), NO2, CN, CO2H, CO(C1-4alifat), CO2(C1-4alifat), O(haloC1-4alifat) ili haloC1-4alifat; J5 je halo, okso, CN, NO2, X1-R ili -(X1)p-Q4; X1 je C1-10alifat; pri čemu su 1 do 3 metilenske jedinice navedenog C1-10alifata po izboru zamijenjene s -NR’-, -O-, -S-, C(=NR’), C(O), S(O)2 ili S(O); pri čemu je X1 po izboru i neovisno supstituiran s 1 do 4 pojavljivanja od NH2, NH(C1-4alifat), N(C1-4alifat)2, halogenom, C1-4alifat, OH, O(C1-4alifat), NO2, CN, CO2H, CO2(C1-4alifat), C(O)NH2, C(O)NH(C1-4alifat), C(O)N(C1-4alifat)2, SO(C1-4alifat), SO2(C1-4alifat), SO2NH(C1-4alifat), SO2NH(C1-4alifat), NHC(O)(C1-4alifat), N(C1-4alifat)C(O)(C1-4alifat), pri čemu je navedeni C1-4alifat po izboru supstituiran s 1 do 3 pojavljivanja halo; Q4 je zasićeni ili nezasićeni monociklički prsten s 3 do 8 članova koji ima 0 do 4 heteroatoma neovisno odabrana između dušika, kisika ili sumpora, ili zasićenog ili nezasićenog bicikličkog prstena s 8 do 10 članova koji ima 0 do 6 heteroatoma neovisno odabrana između dušika, kisika ili sumpora; svaki Q4 je po izboru supstituiran s 1 do 5 JQ4; JQ4 je halo, CN ili C1-4alkil pri čemu su do 2 metilenske jedinice po izboru zamijenjene s O, NR*, S, C(O), S(O), ili S(O)2; R je H ili C1-4alkil pri čemu je navedeni C1-4alkil po izboru supstituiran s 1 do 4 halo; J2 je halo; CN; aromatski ili nearomatski monociklički prsten s 5 do 6 članova koji ima 0 do 3 heteroatoma odabrana između kisika, dušika ili sumpora; ili C1-10alifatska skupina u kojoj su do 2 metilenske jedinice po izboru zamijenjene s O, NR’’, C(O), S, S(O) ili S(O)2; pri čemu je navedena C1-10alifatska skupina po izboru supstituirana s 1 do 3 halo ili CN; i navedeni monociklički prsten je po izboru supstituiran s 1 do 3 pojavljivanja halo; CN; C3-6cikloalkil; heterociklil s 3 do 7 članova koji sadržava 0 do 2 heteroatoma odabrana između kisika, dušika, ili sumpora; ili C1-4alkil pri čemu je do jedna metilenska jedinica alkilnog lanca po izboru zamijenjena s O, NR’’, ili S; i pri čemu je navedeni C1-4alkil po izboru supstituiran s 1 do 3 halo; q je 0, 1 ili 2; p je 0 ili 1; i R’, R’’, i R* su svaki neovisno H, C1-4alkil ili je odsutan; pri čemu je navedeni C1-4alkil po izboru supstituiran sa 1 do 4halo.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da Y je C1-C6alifatski lanac u kojem je jedna metilenska jedinica alkilnog lanca po izboru zamijenjena s C(O) ili -NR0-; R5 je monociklički potpuno zasićen, djelomično nezasićen ili aromatski prsten s 3 do 7 članova koji sadržava 0 do 4 heteroatoma neovisno odabrana između dušika, kisika ili sumpora; ili biciklički, potpuno zasićen, djelomično nezasićeni ili aromatski prsten s 8 do 10 članova koji sadržava 0 do 6 heteroatoma neovisno odabrana između dušika, kisika, ili sumpora; R5 je po izboru supstituiran s 1 do 5 J5 skupina; JZ1 je -(X)t-CN, C1-C6alkil ili -(X)R-Z; X1 je C1-10alifat; pri čemu su 1 do 3 metilenske jedinice navedenog C1-10alifata po izboru zamijenjene s -NR’-, -O-, -S-, C(O), S(O)2 ili S(O); pri čemu je X1 po izboru i neovisno supstituiran s 1 do 4pojavljivanja NH2, NH(C1-4alifat), N(C1-4alifat)2, halogen, C1-4alifat, OH, O(C1-4alifat), NO2, CN, CO2H, CO2(C1-4alifat), C(O)NH2, C(O)NH(C1-4alifat), C(O)N(C1-4alifat)2, SO(C1-4alifat), SO2(C1-4alifat), SO2NH(C1-4alifat), SO2NH(C1-4alifat), NHC(O)(C1-4alifat), N(C1-4alifat)C(O)(C1-4alifat), pri čemu je navedeni C1-4alifat po izboru supstituiran s 1 do 3 pojavljivanja halo.
3. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačen time, da je Y NH; R5 je monociklički aril ili heteroarilni prsten s 5 do 6 članova koji ima 0 do 3 heteroatoma neovisno odabrana između dušika, kisika ili sumpora, R5 je po izboru kondenziran na aromatični prsten s 5 do 6 članova koji sadržava 0 do 2 heteroatoma odabrana između N, O ili S; svaki R5 je po izboru supstituiran s 1 do 5 J5 skupina; L je -C(O)- ili -SO2-; R1 je H, ili C1-C6alkil; R2 je -(C2-C6alkil)-Z ili ciklički prsten s 4 do 8 članova koji sadržava 0 do 2 atoma dušika; pri čemu je navedeni prsten vezan preko atoma ugljika i po izboru je supstituiran s jednom pojavom JZ; ili R1 i R2, zajedno s atomom na koji su vezani, tvore heterociklički prsten s 4 do 8 članova koji sadržava 1 do 2 atoma dušika; pri čemu je navedeni heterociklički prsten po izboru supstituiran s jednom pojavom JZ1; JZ1 je -(X)t-CN, C1-C6alkil ili -(X)r-Z; R3 je H ili C1-C2alkil; R4 je H ili C1-C6 alkil; ili R3 i R4, zajedno s atomom na koji su vezani, tvore heterociklički prsten s 4 do 8 članova koji sadržava 1 do 2 heteroatoma odabrana između kisika, dušika ili sumpora; pri čemu je navedeni prsten po izboru supstituiran s jednom pojavom JZ; J5 je halogen, NO2, CN, O(haloC1-4alifat), haloC1-4alifat ili C1-6alifatska skupina u kojoj se do 2 metilenske jedinice se po izboru zamjenjuju s C(O), O ili NR’; i J2 je halo, C1-C2alkil po izboru supstituiran s 1 do 3 fluora, ili CN; na primjer, pri čemu je L -C(O)-, m je 0, a R1 i R2, zajedno s atomom na koji su vezani, tvore heterociklički prsten s 4 do 8 članova koji sadržava 1 do 2 atoma dušika; na primjer, pri čemu je navedeni heterociklil pirolidinil, piperidinil, piperazinil, azepanil ili 1,4-diazepanil.
4. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time, da je m 0, q je 0, a -L-NR1R2 je C(O)pirolidinil, C(O)piperidinil, C(O)piperazinil, C(O)azepanil, C(O) 1,4-diazepanil, C(O)NH-piperidinil, C(O)NHCH2CH2-pirolidinil, C(O)NHCH2CH2-piperidinil, CON(CH3)CH2CH2N(CH3)2, pri čemu je navedeni pirolidinil, piperidinil, piperazinil, azepanil ili 1,4-diazepanil po izboru supstituiran s C1-4alkil ili N(C1-4alkil)2.
5. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time, da je J2 halo, CN, fenil, oksazolil ili C1-6alifatska skupina pri čemu su do 2 metilenske jedinice po izboru zamijenjene s O, NR’’, C(O), S, S(O) ili S(O)2; navedena C1-6alifatska skupina je po izboru supstituirana s 1 do 3 fluora ili CN.
6. Spoj u skladu s patentnim zahtjevom 1 ili 2 koji ima formulu IIA: [image] naznačen time, da Prsten A je heteroarilni prsten s 5 članova odabran između [image] Y je C1-C4alkilni lanac pri čemu je jedna metilenska jedinica alkilnog lanca po izboru zamijenjena s -NR0-; Q je monociklički aromatski prsten s 5 do 6 članova koji sadržava 0 do 4 heteroatoma neovisno odabrana između dušika, kisika ili sumpora; ili biciklički aromatski prsten s 8 do 10 članova koji sadržava 0 do 6 heteroatoma neovisno odabrana između dušika, kisika ili sumpora; R5 je monociklički aril ili heteroarilni prsten s 5 do 6 članova koji ima 0 do 3 heteroatoma neovisno odabrana između dušika, kisika ili sumpora, R5 je po izboru kondenziran na aromatični prsten s 5 do 6 članova koji sadržava 0 do 2 heteroatoma odabrana između N, O ili S; svaki R5 je po izboru supstituiran s 1 do 5 J5 skupina; L je -C(O)- ili -SO2-; R1 je H, ili C1-C6alkil; R0 je H ili C1-C6 alkil; R2 je C1-C6alkil, -(C2-C6alkil)-Z ili ciklički prsten s 4 do 8 članova koji sadržava 0 do 2 atoma dušika; pri čemu je navedeni prsten vezan preko ugljikovog atoma i po izboru je supstituiran s jednom pojavom JZ; ili R1 i R2, zajedno s atomom na koji su vezani, tvore heterociklički prsten s 4 do 8 članova koji sadržava 1 do 2 heteroatoma odabrana između dušika, sumpora ili kisika; pri čemu je navedeni heterociklički prsten po izboru zamijenjen s jednim pojavljivanjem JZ1; JZ1 je (X)t-CN, C1-C6alkil ili -(X)r-Z; X je C1-C4alkil; svaki t, r i m je neovisno 0 ili 1; Z je -NR3R4; R3 je H ili C1-C2alkil; R4 je H ili C1-C6 alkil; ili R3 i R4, zajedno s atomom na koji su vezani, tvore heterociklički prsten s 4 do 8 članova koji sadržava 1 do 2 heteroatoma odabrana između kisika, dušika ili sumpora; pri čemu je navedeni prsten po izboru supstituiran s jednom pojavom JZ; JZ je NH2, NH(C1-4alifat), N(C1-4alifat)2, halogen, C1-4alifat, OH, O(C1-4alifat), NO2, CN, CO2H, CO(C1-4alifat), CO2(C1-4alifat), O(haloC1-4alifat) ili haloC1-4alifat; J5 je halogen, NO2, CN, O(haloC1-4alifatska), haloC1-4alifatska ili C1-6alifatska grupa u kojoj su do 2 metilenske jedinice po izboru zamijenjene s C(O), O ili NR’; J2 je halo; CN; fenil; oksazolil; ili C1-6alifatska skupina u kojoj su do 2 metilenske jedinice po izboru zamijenjene s O, NR’’, C(O), S, S(O) ili S(O)2; navedena C1-6alifatska skupina je po izboru supstituirana s 1 do 3 fluora ili CN; R’ i R’’ su svaki neovisno H ili C1-C4 alkil; q je 0, 1 ili 2, p je 0 ili 1; na primjer pri čemu je Q fenil ili piridil, na primjer, pri čemu je spoj odabran između sljedećeg: Tablica IIA-2 (1. dio) [image] Tablica IIA-2 (2. dio) [image] [image]
7. Spoj u skladu s patentnim zahtjevom 1 koji ima formulu IA': [image] ili njegova farmaceutski prihvatljiva sol; naznačen time, da Y je C1-C4alkilni lanac pri čemu je jedna metilenska jedinica alkilnog lanca po izboru zamijenjena s -NR0-; G je O ili S; Q je monociklički aromatski prsten s 5 do 6 članova koji sadržava 0 do 4 heteroatoma neovisno odabrana između dušika, kisika ili sumpora; ili biciklički aromatski prsten s 8 do 10 članova koji sadržava 0 do 6 heteroatoma neovisno odabrana između dušika, kisika ili sumpora; R5 je monociklički potpuno zasićen, djelomično nezasićen ili aromatski prsten s 3 do 7 članova koji sadržava 0 do 4 heteroatoma neovisno odabrana između dušika, kisika ili sumpora; ili biciklički potpuno zasićen, djelomično nezasićeni ili aromatski prsten s 8 do 10 članova koji sadržava 0 do 6 heteroatoma neovisno odabrana između dušika, kisika, ili sumpor; R5 je po izboru supstituiran s 1 do 5 J5 skupina; L je C1-4alkilni lanac u kojem su do dvije metilenske jedinice alkilnog lanca po izboru zamijenjene s O, NR6, S, -C(O)-, -SO- ili -SO2-; R0 je H ili C1-C6 alkil; R1 je H ili C1-C6alkil; R2 je H, C1-C6alkil, -(C2-C6alkil)-Z ili ciklički prsten s 4 do 8 članova koji sadržava 0 do 2 atoma dušika; pri čemu je navedeni prsten vezan preko ugljikovog atoma i po izboru je supstituiran s jednom pojavom JZ; ili R1 i R2, zajedno s atomom na koji su vezani, tvore heterociklički prsten s 4 do 8 članova koji sadržava 1 do 2 heteroatoma odabrana između dušika, sumpora ili kisika; pri čemu je navedeni heterociklički prsten po izboru zamijenjen s jednim pojavljivanjem JZ1; JZ1 je -(X)t-CN, C1-C6alkil ili -(X)R-Z; X je C1-C4alkil; svaki t, r i m je neovisno 0 ili 1; Z je -NR3R4; R3 je H ili C1-C2alkil; R4 je H ili C1-C6 alkil; ili R3 i R4, zajedno s atomom na koji su vezani, tvore heterociklički prsten s 4 do 8 članova koji sadržava 1 do 2 heteroatoma odabrana između kisika, dušika ili sumpora; pri čemu je navedeni prsten po izboru supstituiran s jednom pojavom JZ; R6 je H, ili C1-C6alkil; JZ je neovisno NH2, NH(C1-4alifat), N(C1-4alifat)2, halogen, C1-4alifat, OH, O(C1-4alifat), NO2, CN, CO2H, CO(C1-4alifat), CO2(C1-4alifat), O(haloC1-4alifat) ili haloC1-4alifat; J5 je halo, okso, CN, NO2, X1-R ili -(X1)p-Q4, X1 je C1-10alifat; pri čemu su 1 do 3 metilenske jedinice navedenog C1-10alifata po izboru zamijenjene s -NR’-, -O-, -S-, C(O), S(O)2 ili S(O); pri čemu je X1 po izboru i neovisno supstituiran s 1 do 4pojavljivanja NH2, NH(C1-4alifat), N(C1-4alifat)2, halogen, C1-4alifat, OH, O(C1-4alifat), NO2, CN, CO2H, CO2(C1-4alifat), C(O)NH2, C(O)NH(C1-4alifat), C(O)N(C1-4alifat)2, SO(C1-4alifat), SO2(C1-4alifat), SO2NH(C1-4alifat), SO2NH(C1-4alifat), NHC(O)(C1-4alifat), N(C1-4alifat)C(O)(C1-4alifat), pri čemu je navedeni C1-4alifat po izboru supstituiran s 1 do 3 pojavljivanja halo; Q4 je zasićeni ili nezasićeni monociklički prsten s 3 do 8 članova koji ima 0 do 4 heteroatoma neovisno odabrana između dušika, kisika ili sumpora, ili zasićeni ili nezasićeni biciklički prsten s 8 do 10 članova koji ima 0 do 6 heteroatoma neovisno odabrana između dušika, kisika ili sumpora; svaki Q4 je po izboru supstituiran s 1 do 5 JQ4; JQ4 je halo, CN ili C1-4alkil pri čemu su do 2 metilenske jedinice po izboru zamijenjene s O, NR*, S, C(O), S(O), ili S(O)2; R je H ili C1-4alkil pri čemu je navedeni C1-4alkil po izboru supstituiran s 1 do 4halo; J2 je halo; CN; aromatski ili nearomatski monociklički prsten s 5 do 6 članova koji ima 0 do 3 heteroatoma odabrana između kisika, dušika ili sumpora; ili C1-10alifatska skupina u kojoj su do 2 metilenske jedinice po izboru zamijenjene s O, NR’’, C(O), S, S(O) ili S(O)2; pri čemu je navedena C1-10alifatska skupina po izboru supstituirana s 1 do 3 halo ili CN; i navedeni monociklički prsten je po izboru supstituiran s 1 do 3 halo; CN; C3-6cikloalkil; s 3 do 7 članova heterociklil koji sadržava 0 do 2 heteroatoma odabrana između kisika, dušika ili sumpora ili C1-4alkila pri čemu je do jedna metilenska jedinica alkilnog lanca po izboru zamijenjena s O, NR’’ ili S; q je 0, 1 ili 2, p je 0 ili 1; i R’, R’’, i R* su svaki neovisno H, C1-4alkil ili je odsutan; pri čemu je navedeni C1-4alkil po izboru supstituiran s 1 do 4halo; na primjer pri čemu je J5 halo, CN, fenil, oksazolil ili C1-6alifatska skupina pri čemu su do 2 metilenske jedinice po izboru zamijenjene s O, NR’, C(O), S, S(O) ili S(O)2; navedena C1-6alifatska skupina je po izboru supstituirana s 1 do 3 fluora ili CN.
8. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time, da je Q fenil ili piridil, i a) pri čemu je barem još jedna metilenska jedinica C1-6alifatske skupine po izboru zamijenjena heteroatomom odabranim iz skupine koju čine O, NR’’ i S; b) pri čemu je Q supstituiran s jednim ili dva J2, pri čemu je J2 C1-6alifatska skupina u kojoj se do 2 metilenske jedinice po izboru zamjenjuju s O ili NR’’; na primjer, pri čemu je J2 -OCH3, -OCH2CH2N(CH3)2, -NHCH2CH2N(CH3)2 ili piperazinil; ili c) pri čemu je Q supstituiran na para položaju sa -SO2(C1-4alkil), -SO2(C1-4alkil)N(C1-4alkil)2, C(O)N(C1-4alkil)2, C(O)(1,4-diazepanil), CO(azepanil), C(O)(piperazinil) ili C(O)(piperidinil); ili, pri čemu je Q po izboru supstituiran u para položaju s J2, pri čemu je J2 -SO2(C1-4alkil), -SO2(C3-6cikloalkil), -SO2(3-6 članova heterociklil), -SO2(C1-4alkil)N(C1-4alkil)2, -C(O)(C1-4alkil), -(C1-4alkil)N(C1-4alkil)2, ili -NHC(O)(Ci_4alkil); ili d) pri čemu je Q po izboru supstituiran u orto položaju s J2, pri čemu je J2 C1-4alkil, -C≡C-(C1-4alkil), CH=CH2, CH=CHF, O(C1-4alkil), NH(C1-4alkil), N(C1-4alkil)2, -(C1-4alkil)OH, -(C1-4alkil)O(C1-4alkil), -(C1-4alkil)NH2, -(C1-4alkil)NH(C1-4alkil), -(C1-4alkil)N(C1-4alkil)2, -(C1-4alkil)CN, CO(C1-4alkil), CON(C1-4alkil)2, C(O)O(C1-4alkil), S(C1-4alkil), -S-(C1-4alkil)NH2, S(O)(C1-4alkil)NH2, S(O )2(C1-4alkil)OH, S(O)(C1-4alkil)NHC(O)O(t-butil), NHS(O)2(C1-4alkil), halo ili CN; na primjer, pri čemu je J2 CH2CH2OH, SCH(CH3)2, -C≡CCH3, halo, CN, CON(CH3)2, CH2CN, S(O)CH2CH2NH2, SCH2CH2NH2, C(O)OCH3, CH2N(CH3)2, S(O)CH2CH2NHBOC, N(CH3)2, NHSO2CH3, CH=CHF, CH2OCH3, CH=CH2, SCH2CH3 ili -CH=CH; ili e) pri čemu je Q po izboru supstituiran u meta položaju s J2 pri čemu je J2 C1-4alkil, C1-4alkoksi, halo, haloC1-4alkil, haloC1-4alkoksil, CN, SO2(C1-4alkil), NHSO2(C1-4alkil), C(O)(C1-4alkil), C(O)NH2, NHC(O)(C1-4alkil), -(C1-4alkil)-OH, -(C1-4alkil)-O(C1-4alkil), -(C1-4alkil)-NH2, -(C1-4alkil)-N (C1-4alkil)2, ili -(C1-4alkil)NH(C1-4alkil); ili f) pri čemu je Q fenil; i Q je po izboru supstituiran u orto položaju s jednim J2, pri čemu je J2 C1-C4alkil, NH2, NHC(O)CH3, O(C1-C4alkil), CH2OH, CH2OCH3, CH2CH2OCH3, CH2CN, CN, CH2C(O)NH2, OH, OCF3, CF3, CHF2, -CH=CHF, NHC(O)CH3, C(O)CH3, C(O)NH2, SCH3, S(O)CH3, S(O)CH2CH3, SO2CH(CH3)2, -C≡CH2, oksazolil, ili fenil; na primjer, pri čemu je Q supstituiran u orto položaju s J2, pri čemu je J2 CH2OH, CHF2, S(O)CH3, ili S(O)CH2CH3.
9. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time, da p je 1; na primjer pri čemu je Q fenil, piridil ili naftil; na primjer pri čemu je navedeni piridil 3-piridil ili 4-piridil.
10. Spoj u skladu s patentnim zahtjevom 9, naznačen time, da L je -C(O)- ili -SO2-; na primjer pri čemu R1 i R2, zajedno s atomom na koji su vezani, tvore heterociklički prsten s 4 do 8 članova koji sadržava 1 do 2 heteroatoma odabrana između dušika, sumpora ili kisika; na primjer pri čemu je navedeni heterociklički prsten odabran između pirolidinila, piperidinila, piperazinila, morfolinila, 1,4-diazepanila, ili 1,4-oksazepanila; na primjer pri čemu je navedeni heterociklički prsten po izboru supstituiran s halo, CN, C1-6alifatičnim, haloC1-6alifatm, -C(O)O(C1-6alifat), C(O)H, C(O)(C1-6alifat), P(O)(OC1-4alkil)2, NH(C1-6alifat) ili N(C1-6alifat)2.
11. Spoj u skladu s patentnim zahtjevom 6 ili patentnim zahtjevom 7, naznačen time, da je m 0, a R5 je tienil, tiazolil, furanil, pirolidinil, azetidinil, piperidinil, piperazinil, morfolinil, piridinonil, piridil, tetrahidropiridinil, tetrahidroizokinolinil, 1,4-diazepanil, azabiciklo[2.2.1]heptanil ili fenil; na primjer pri čemu je R5 fenil, piperidinil ili tienil; na primjer pri čemu je Q po izboru supstituiran u para položaju sa -SO2(C1-4alkil), -SO2(C1-4alkil)N(C1-4alkil)2, C(O)N(C1-4alkil)2, C(O)(1,4-diazepanil), C(O)(piperazinil) ili C(O)(piperidinil); na primjer pri čemu je R5 po izboru supstituiran s 1 do 2 J5 grupe, pri čemu je J5 odabran između halo, CN, NO2, X1-R ili -(X1)p-Q4; p je 0-1; X1 je C1-10alifat pri čemu su 1 do 3 metilenske jedinice navedenog C1-6alifata po izboru zamijenjene s -NR’-, -O-, -S-, C(=NH)-, C(O), S(O)2 ili S(O); R je H; i Q4 je monociklički prsten s 3 do 6 članova koji sadržava 0 do 2 heteroatoma odabrana između O ili N, pri čemu je X1 po izboru supstituiran s 1 do 3 pojavljivanja halo ili CN; na primjer pri čemu je J5 C1-10alifat lanac pri čemu su 1 do 2 metilenske jedinice X1 zamijenjene s -O- ili-NR’-; na primjer pri čemu je R5 piperidinil po izboru supstituiran s NH2 ili -(C1-4alkil)NH2; na primjer pri čemu je R5 tienil po izboru supstituiran sa CN, C1-6alkil, -(C1-4alkil)NH2, -(C1-4alkil)NH(C1-6alkil), -(C1-4alkil)N(C1-6alkil)2, O(C1-6alkil), pirolidinil, pri čemu je navedeni alkil po izboru supstituiran s 1 do 3 halo; na primjer pri čemu je Q4 po izboru supstituirani cikloalkilni prsten s 3 do 6 članova; na primjer pri čemu je Q4 po izboru supstituirani heterociklički prsten s 3 do 6 članova odabran između pirolidinila, azetidinila ili tienil; na primjer pri čemu je J5 halo, C1-6alkil, NO2, CN, C1-6alkil, -CH=CH2, OH, OCH3, OCH2CH3, OCH(CH3)2, NH2, CH2NH2, CH2OH, CH(CH3)NHCH3, C(CH3)2NH2, CH2CH2NH2, CH2CH2OH, CH2NHCH3, CH2N(CH3)2, CH(CH3)NH2, CH(CH3)NHC(O)O(CH3)3, CH2NHC(CH3)2, CH2NHCH2CHF2, CH2NHCH2CH(CH3)OH, CH2NHCH2C(CH3)2OH, CH2NHCH2CH(OH)-ciklopropil, CH2NHCH2CH2N(CH3)2, CH2NHCH(CH2CH3)3, CH2NHCH3, CH2NHCH2CH3, CH2NHCH2CH2CH3, CH2NH-ciklopropil, CH2NHCH2CH2OH, CH2NHCH2CH2OCH3, CH2NHCH2CH2OCH2CH2OH, azetidinil, pirolidinil, CF3, C(=NH)NH2, C(=NH)NH(CH3), tienil, CH2NH-ciklopropil, CH2NH(CH2OH)3, OCH2CH2OH, OCH2CH2CH2OH, OCH2CH2NHC(O)OC(CH3)3, CH2NHC(O)O(CH3)3 ili CH2OC(O)CH3.
12. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 2, koji ima formulu IA-iii: [image] naznačen time, da Prsten A je [image] ili [image] , J5o je H, F, Cl, C1-4alifat, O(C1-3alifat) ili OH; J5p je [image] J5p1 je H, C1-4alifat, oksetanil, tetrahidrofuranil, tetrahidropiranil; pri čemu je J5p1 po izboru supstituiran s 1 do 2 pojave OH ili halo; J5p2 je H, metil, etil, CH2F, CF3 ili CH2OH; J2o je H, CN ili SO2CH3; J2m je H, F, Cl ili metil; J2p je -SO2(C1-6alkil), -SO2(C3-6cikloalkil), -SO2(heterociklil s 4 do 6 članova), -SO2(C1-4alkil)N(C1-4alkil)2, ili -SO2(C1-4alkil)-(heterociklil s 4 do 6 članova), pri čemu navedeni heterociklil sadržava 1 heteroatom odabran između kisika, dušika ili sumpora; i pri čemu je navedeni J2p po izboru supstituiran s 1 do 3 pojave halo, OH ili O(C1-4alkil).
13. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je odabran između sljedećeg: Tablica IA-1 [image] Tablica IA-2 [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image]
14. Spoj, naznačen time, da je odabran između sljedećeg: [image]
15. Farmaceutski pripravak, naznačen time, da sadržava spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 14 i farmaceutski prihvatljiv nosač.
16. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 14, ili njegova farmaceutski prihvatljiva sol, ili njegov farmaceutski pripravak, u skladu s patentnim zahtjevom 15, naznačen time, da se upotrebljava u liječenju raka kod pacijenata.
17. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 14, ili farmaceutski pripravak iz patentnog zahtjeva 15, za uporabu u skladu s patentnim zahtjevom 16, naznačen time, da upotreba podrazumijeva dodatno terapeutsko sredstvo odabrano između agensa koji oštećuje DNA; pri čemu je navedeno dodatno terapeutsko sredstvo prikladno za bolest koja se liječi; i navedeno dodatno terapeutsko sredstvo se primjenjuje zajedno sa navedenim spojem kao pojedinačni oblik doze ili odvojeno od navedenog spoja kao dio višestrukog oblika doziranja; na primjer, pri čemu je navedeno sredstvo koje oštećuje DNA odabrano za kemoterapiju ili liječenje zračenjem; na primjer, pri čemu je navedeno sredstvo koje oštećuje DNA odabrano između ionizirajućeg zračenja, radiomimetičkog neokarzinostatina, sredstva za platiniranje, inhibitora topo I, inhibitora topo II, antimetabolita, sredstva za alkiliranje, alkil sulfonata, antimetabolita ili antibiotika; na primjer, pri čemu je navedeno sredstvo koje oštećuje DNA odabrano između ionizirajućeg zračenja, sredstva za platiniranje, inhibitora topo I, inhibitora topo II ili antibiotika; na primjer, pri čemu je navedeno sredstvo za platiniranje odabrano između cisplatina, oksaliplatina, karboplatina, nedaplatina ili satraplatina; navedeni inhibitor topo I je odabran između kamptotecina, topotekana, irinotekana/SN38, rubitekana; navedeni inhibitor topo II je odabran između etopozida; navedeni antimetabolit je odabran između metotreksata, pemetrekseda, tioguanina, fludarabina, kladribina, citarabina, gemcitabina, 6-merkaptopurina ili 5-fluorouracila; navedeno alkilirajuće sredstvo je odabrano između dušikovih iperita, nitrozourea, triazena, alkil sulfonata, prokarbazina ili aziridina; i navedeni antibiotik je odabran iz obitelji Hydroxyurea, Anthracyclines, Anthracenediones ili Streptomyces.
18. Spoj ili pripravak za upotrebu u skladu s patentnim zahtjevom 16, naznačen time, da upotreba nadalje sadržava sredstvo koje oštećuje DNA, pri čemu je navedeno sredstvo koje oštećuje DNA sredstvo za platiniranje ili ionizirajuće zračenje; na primjer, pri čemu je navedeno sredstvo za platiniranje odabrano između cisplatina, oksaliplatina, karboplatina, nedaplatina, lobaplatina, triplatin tetranitrata, picoplatina, satraplatina, ProLindaca i aroplatina; navedeni inhibitor topo I je odabran između kamptotecina, topotekana, irinotekana/SN38, rubitekana i belotekana; navedeni inhibitor topo II je odabran između etopozida, daunorubicina, doksorubicina, aklarubicina, epirubicina, idarubicina, amrubicina, pirarubicina, valrubicina, zorubicina i teniposida; navedeni antimetabolit je odabran između aminopterina, metotreksata, pemetrekseda, raltitreksada, pentostatina, kladribina, klofarabina, fludarabina, tioguanina, merkaptopurina, fluorouracila, kapecitabina, tegafura, karmofura, floksuridina, citarabina, gecitabidina, citarabina, gecitabidina; navedeno alkilirajuće sredstvo odabrano je između mekloretamina, ciklofosfamida, ifosfamida, trofosfamida, klorambucila, melfalana, prednimustina, bendamustina, uramustina, estramustina, karmustina, lomustina, semustina, fotemustina, nimustina, ranimustina, streptozocina manosulfana, treosulfana, karboquona, tioTEPA, triaziquona, trietilenmelamina, prokarbazina, dekarbazina, temozolomida, altretamina, mitobronitola, aktinomicina, bleomicina, mitomicina i plikamicina.
19. Spoj ili pripravak za uporabu u skladu s patentnim zahtjevom 16 ili 18, ili patentnim zahtjevom 17, kada ovisi o patentnom zahtjevu 16, naznačen time, da je navedeni rak čvrsti tumor odabran od sljedećih karcinoma: Oralni: usna šupljina, usna, jezik, usta, ždrijelo; Srčani: sarkom (angiosarkom, fibrosarkom, rabdomiosarkom, liposarkom), miksom, rabdomiom, fibrom, lipom i teratom; Pluća: bronhogeni karcinom (skvamozni ili epidermoidni, nediferencirani mali stanični, nediferencirani veliki stanični, adenokarcinom), alveolarni (bronhiolarni) karcinom, bronhijalni adenom, sarkom, limfom, hondromatski hamartom, mezoteliom; Gastrointestinalni: jednjak (karcinom skvamoznih stanica, grkljan, adenokarcinom, leiomiosarkom, limfom), želudac (karcinom, limfom, leiomiosarkom), gušterača (duktalni adenokarcinom, inzulinom, glukagonom, gastrinom, karcinoidni tumor, vipom), tanko crijevo (adenokarcinom, limfom, karcinoidni tumori, Karposijev sarkom, leiomiom, hemangiom, lipom, neurofibrom, fibrom), debelo crijevo (adenokarcinom, tubularni adenom, vilozni adenom, hamartom, leiomiom), debelo crijevo, debelo crijevo-rektum, kolorektalni; rektum, Genitourinarni trakt: bubrezi (adenokarcinom, Wilmov tumor [nefroblastom], limfom), mokraćni mjehur i uretra (karcinom skvamoznih stanica, karcinom prijelaznih stanica, adenokarcinom), prostata (adenokarcinom, sarkom), testisa (seminom, teratom, embrionalni karcinom, teratokarcinom, koriokarcinom, sarkom, karcinom intersticijskih stanica, fibrom, fibroadenom, adenomatoidni tumori, lipom); Jetra: hepatom (hepatocelularni karcinom), kolangiokarcinom, hepatoblastom, angiosarkom, hepatocelularni adenom, hemangiom, bilijarni prolazi; Kosti: osteogeni sarkom (osteosarkom), fibrosarkom, maligni fibrozni histiocitom, hondrosarkom, Ewingov sarkom, maligni limfom (sarkom retikulumskih stanica), multipli mijelom, maligni tumor divovskih stanica, hordom, osteohronfrom (osteokartilaginozna egzostoza), benigni hondrom, hondroblastom, hondromiksofibrom, osteoidni osteom i tumori divovskih stanica; Živčani sustav: lubanja (osteom, hemangiom, granulom, ksantom, osteitis deformans), moždana ovojnica (meningiom, meningiosarkom, gliomatoza), mozak (astrocitom, meduloblastom, gliom, ependimom, germinom [pinealom], multiformni glioblastom, oligodendrogliom, švanom, retinoblastom, kongenitalni tumori), neurofibrom leđne moždine, meningiom, gliom, sarkom); Ginekološki: maternica (endometrijski karcinom), cerviks (karcinom vrata maternice, predtumorska cervikalna displazija), jajnici (karcinom jajnika [serozni cistadenokarcinom, mucinozni cistadenokarcinom, neklasificirani karcinom], tumori granuloza-tekalnih stanica, tumori Sertoli-Leydigovih stanica, disgerminom, maligni teratom), vulva (karcinom skvamoznih stanica, intraepitelni karcinom, adenokarcinom, fibrosarkom, melanom), vagina (karcinom bistrih stanica, karcinom skvamoznih stanica, botrioidni sarkom (embrionalni rabdomiosarkom), karcinom jajovoda; grudi; Koža: maligni melanom, karcinom bazalnih stanica, karcinom skvamoznih stanica, Karposijev sarkom, keratoakantom, madeži displastičnih mrlja, lipom, angiom, dermatofibrom, keloidi, psorijaza, Štitnjača: papilarni karcinom štitnjače, folikularni karcinom štitnjače; medularni karcinom štitnjače, multipla endokrina neoplazija tip 2A, multipla endokrina neoplazija tip 2B, obiteljski medularni karcinom štitnjače, feokromocitom, paragangliom; i Nadbubrežne žlijezde: neuroblastom.
20. Spoj ili pripravak za uporabu u skladu s patentnim zahtjevom 16 ili 19, naznačen time, da je navedeni rak odabran između raka pluća, raka glave i vrata, raka gušterače, raka želuca i raka mozga.
21. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 da 14, ili njegova farmaceutski prihvatljiva kompozicija, naznačen time, da se koristi za promicanje stanične smrti u stanicama raka, sprječavanju popravka stanica od oštećenja DNA ili preosjetljivosti stanica na sredstva koja oštećuju DNA.
22. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 14, za uporabu u skladu s patentnim zahtjevom 21, naznačen time, da a) navedena stanica je stanica raka koja ima defekte u ATM signalnoj kaskadi; na primjer pri čemu je navedeni defekt promijenjena ekspresija ili aktivnost jednog ili više od sljedećeg: ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1 ili H2AX; ili pri čemu navedena stanica raka ima promijenjenu ekspresiju ili aktivnost jednog ili više od sljedećeg: K-Ras, N-Ras, H-Ras, Raf, Myc, Mos, E2F, Cdc25A, CDC4, CDK2, ciklin E, ciklin A i Rb; ili b) navedena stanica je stanica raka koja eksprimira onkogene koji oštećuju DNA.
HRP20220581TT 2008-12-19 2009-12-18 Spojevi korisni kao inhibitori atr kinaze HRP20220581T1 (hr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US13942408P 2008-12-19 2008-12-19
US13942608P 2008-12-19 2008-12-19
US13942008P 2008-12-19 2008-12-19
US13942908P 2008-12-19 2008-12-19
US18179409P 2009-05-28 2009-05-28
US21910009P 2009-06-22 2009-06-22
EP17205270.6A EP3354650B1 (en) 2008-12-19 2009-12-18 Compounds useful as inhibitors of atr kinase

Publications (1)

Publication Number Publication Date
HRP20220581T1 true HRP20220581T1 (hr) 2022-06-10

Family

ID=41683104

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20220581TT HRP20220581T1 (hr) 2008-12-19 2009-12-18 Spojevi korisni kao inhibitori atr kinaze
HRP20180385TT HRP20180385T1 (hr) 2008-12-19 2018-03-05 Derivati pirazina korisni kao inhibitori atr kinaze

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20180385TT HRP20180385T1 (hr) 2008-12-19 2018-03-05 Derivati pirazina korisni kao inhibitori atr kinaze

Country Status (29)

Country Link
US (7) US8841308B2 (hr)
EP (3) EP4059932A1 (hr)
JP (5) JP5753093B2 (hr)
KR (3) KR101958632B1 (hr)
CN (4) CN106496209B (hr)
AR (1) AR074822A1 (hr)
AU (3) AU2009327357C1 (hr)
BR (1) BRPI0924084B1 (hr)
CA (2) CA3013000C (hr)
CY (1) CY1120002T1 (hr)
DK (2) DK2376485T3 (hr)
ES (2) ES2921576T3 (hr)
HK (1) HK1259148A1 (hr)
HR (2) HRP20220581T1 (hr)
HU (1) HUE036068T2 (hr)
IL (3) IL213613A (hr)
LT (2) LT2376485T (hr)
MX (1) MX2011006503A (hr)
NO (1) NO2376485T3 (hr)
NZ (1) NZ593969A (hr)
PL (2) PL3354650T3 (hr)
PT (2) PT2376485T (hr)
RS (1) RS56995B1 (hr)
RU (2) RU2604066C2 (hr)
SG (2) SG10201607592PA (hr)
SI (2) SI2376485T1 (hr)
TW (3) TWI543979B (hr)
WO (1) WO2010071837A1 (hr)
ZA (1) ZA201104498B (hr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170015566A (ko) 2008-11-10 2017-02-08 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 화합물
KR101958632B1 (ko) * 2008-12-19 2019-03-15 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 피라진 유도체
US8415381B2 (en) * 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
JP2013529200A (ja) * 2010-05-12 2013-07-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
WO2011143425A2 (en) * 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2011143426A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8969356B2 (en) 2010-05-12 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9096584B2 (en) 2010-05-12 2015-08-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2011143419A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Pyrazines useful as inhibitors of atr kinase
EP2585468A1 (en) 2010-06-23 2013-05-01 Vertex Pharmaceuticals Incorporated Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
US8962623B2 (en) 2011-03-04 2015-02-24 Locus Pharmaceuticals, Inc. Aminopyrazine compounds
TW201247650A (en) 2011-03-16 2012-12-01 Hoffmann La Roche 6,5-heterocyclic propargylic alcohol compounds and uses therefor
WO2012138938A1 (en) * 2011-04-05 2012-10-11 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of tra kinase
ES2699256T3 (es) * 2011-05-23 2019-02-08 Merck Patent Gmbh Piridina y derivados de pirazina
US8822469B2 (en) 2011-06-22 2014-09-02 Vertex Pharmaceuticals Incorporated Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase
EP2723747A1 (en) * 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
JP2014517079A (ja) * 2011-06-22 2014-07-17 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー Ｎ−置換ヘテロシクリルカルボキサミド類
CN103946221B (zh) * 2011-09-16 2016-08-03 诺华股份有限公司 用于治疗囊性纤维化的杂环化合物
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CN103958507A (zh) 2011-09-30 2014-07-30 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物
HUE046429T2 (hu) * 2011-09-30 2020-03-30 Vertex Pharma ATR kináz inhibítoraként használható vegyületek elõállítására szolgáló eljárás
WO2013049720A1 (en) * 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
IN2014CN02501A (hr) * 2011-09-30 2015-06-26 Vertex Pharma
WO2013071094A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8846917B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8841337B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071093A1 (en) * 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
US8841449B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2015515478A (ja) * 2012-04-05 2015-05-28 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物及びそれらの併用療法
CN104640852B (zh) 2012-04-24 2017-04-26 沃泰克斯药物股份有限公司 Dna‑pk抑制剂
WO2014055756A1 (en) 2012-10-04 2014-04-10 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
US8912198B2 (en) 2012-10-16 2014-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
LT3418281T (lt) * 2012-12-07 2021-01-11 Vertex Pharmaceuticals Inc. Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
EP2941425B1 (en) * 2013-01-02 2017-07-12 H. Lundbeck A/S Aminopyridine derived compounds as lrrk2 inhibitors
MA38287B1 (fr) * 2013-01-23 2018-08-31 Astrazeneca Ab Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer
KR102216284B1 (ko) 2013-03-12 2021-02-18 버텍스 파마슈티칼스 인코포레이티드 Dna-pk 억제제
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
DK3057953T3 (en) 2013-10-17 2018-11-19 Vertex Pharma CO CRYSTALS OF (S) -N-METHYL-8- (1 - ((2'-METHYL- [4,5'-BIPYRIMIDIN] -6-YL) AMINO) PROPAN-2-YL) QUINOLIN-4-CARBOXAMIDE AND DEUTERATED DERIVATIVES THEREOF AS DNA-PK INHIBITORS
CN105934435B (zh) 2013-12-06 2019-02-22 沃泰克斯药物股份有限公司 用作atr激酶抑制剂的化合物，其制备，及其放射性标记的衍生物
CN103804312B (zh) * 2014-02-17 2016-04-20 四川百利药业有限责任公司 一类氮杂环化合物及其制备方法和用途
KR20160145780A (ko) 2014-04-24 2016-12-20 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
WO2015162459A1 (en) * 2014-04-24 2015-10-29 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
BR112016023967A2 (pt) 2014-04-24 2017-08-15 Novartis Ag derivados de pirazina como inibidores de fosfatidilinositol 3-cinase
MX2016015874A (es) 2014-06-05 2017-03-27 Vertex Pharma Derivados radiomarcadores de un compuesto de 2-amino-6-fluoro-n-[5 -fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo.
ES2733847T3 (es) 2014-06-17 2019-12-03 Vertex Pharma Método para tratar cáncer usando una combinación de inhibidores de CHK1 y ATR
TWI656121B (zh) 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
EP3207031B1 (en) * 2014-10-13 2021-04-14 Atrin Pharmaceuticals LLC Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
KR102558501B1 (ko) * 2016-01-11 2023-07-21 메리맥 파마슈티컬즈, 인크. 혈관확장성 운동실조증 및 Rad3-관련 단백질(ATR)의 억제
WO2018029117A1 (en) 2016-08-10 2018-02-15 Rheinisch-Westfälische Technische Hochschule Aachen (RWTH) New atr inhibitors for the use in cancer therapy
US11730734B2 (en) * 2016-09-12 2023-08-22 University Of Florida Research Foundation, Incorporated Use of ATR and Chk1 inhibitor compounds
JP7114575B2 (ja) 2016-09-19 2022-08-08 ノバルティス アーゲー Ｒａｆ阻害剤及びｅｒｋ阻害剤を含む治療用組合せ
KR20190062485A (ko) 2016-09-27 2019-06-05 버텍스 파마슈티칼스 인코포레이티드 Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법
EA039513B1 (ru) * 2017-01-09 2022-02-04 Селатор Фармасьютикалз, Инк. Ингибитор атаксии-телеангиэкстазии и rad3-родственного белка (atr) и содержащие его липосомные композиции
JOP20190197A1 (ar) 2017-02-24 2019-08-22 Bayer Pharma AG مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر
WO2018153969A1 (en) 2017-02-24 2018-08-30 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with radium-223 salt
WO2018153972A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combination of atr kinase inhibitors and antiandrogens
WO2018187479A1 (en) 2017-04-04 2018-10-11 Case Western Reserve University Method of modulating ribonucleotide reductase
EP3617196B1 (en) 2017-04-27 2023-06-07 Ishihara Sangyo Kaisha, Ltd. N-(4-pyridyl) nicotinamide compound or salt thereof
KR102641827B1 (ko) 2017-05-02 2024-03-04 노파르티스 아게 병용 요법
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
CA3071760A1 (en) 2017-08-04 2019-02-07 Bayer Pharma Aktiengesellschaft Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors
GB201715410D0 (en) 2017-09-22 2017-11-08 Syngenta Participations Ag Improvements in or relating to organic compounds
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CA3084863A1 (en) 2017-12-08 2019-06-13 Bayer Aktiengesellschaft Predictive markers for atr kinase inhibitors
US11306079B2 (en) 2017-12-21 2022-04-19 Incyte Corporation 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors
WO2019133711A1 (en) * 2017-12-29 2019-07-04 Vertex Pharmaceuticals Incorporated Methods of cancer treatment using an atr inhibitor
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
US20220048997A1 (en) 2018-09-26 2022-02-17 Merck Patent Gmbh Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer
AU2019360608A1 (en) 2018-10-15 2021-06-03 Merck Patent Gmbh Combination therapy utilizing DNA alkylating agents and ATR inhibitors
EP3866805A1 (en) 2018-10-16 2021-08-25 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
EP4097223A4 (en) * 2020-01-30 2024-04-17 The Regents Of The University Of California STRAD-BINDING AGENTS AND USES THEREOF
WO2022063869A2 (en) * 2020-09-24 2022-03-31 Merck Patent Gmbh Compounds for the treatment of viral infections
EP4232037A1 (en) 2020-10-26 2023-08-30 Merck Patent GmbH Atr inhibitors for use in the treatment of viral infections
CN115703768A (zh) * 2021-08-13 2023-02-17 苏州爱科百发生物医药技术有限公司 用作atr激酶抑制剂的化合物
TW202321230A (zh) * 2021-08-13 2023-06-01 大陸商蘇州愛科百發生物醫藥技術有限公司 用作ａｔｒ激酶抑制劑的化合物
CA3181279A1 (en) * 2022-03-24 2023-09-24 Bloom Energy Corporation Fuel cell stack assembly including heat sink inserts
WO2023242302A1 (en) 2022-06-15 2023-12-21 Astrazeneca Ab Combination therapy for treating cancer
CN118255760A (zh) * 2022-12-27 2024-06-28 江苏亚虹医药科技股份有限公司 一种嘧啶类化合物及其制备方法和医药用途
WO2024159286A1 (pt) * 2023-01-30 2024-08-08 Eurofarma Laboratórios S.A. Compostos fenólicos bloqueadores de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits
CN117024413B (zh) * 2023-10-07 2024-01-09 天津匠新致成科技有限公司 3-氨基吡嗪-2-甲酰胺类靶向蛋白水解嵌合体及其制备方法、药物组合物和应用

Family Cites Families (226)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309430A (en) * 1980-06-27 1982-01-05 Merck & Co., Inc. Pyrazinyl-1,2,4-oxadiazole-5-ones, for treatment of edema, and processes for preparing same
JPS62270623A (ja) 1985-12-07 1987-11-25 Daicel Chem Ind Ltd ビス（４−アミノフエニル）ピラジンおよびその製法、ならびにポリイミドおよびその製法
JPS63208520A (ja) 1987-02-26 1988-08-30 Terumo Corp ピラジン誘導体を含有する血小板凝集抑制剤
US5329012A (en) 1987-10-29 1994-07-12 The Research Foundation Of State University Of New York Bis(acyloxmethyl)imidazole compounds
JPH0272372A (ja) 1988-09-07 1990-03-12 Konica Corp 電子写真感光体
JPH0272370A (ja) 1988-09-07 1990-03-12 Konica Corp 電子写真感光体
JPH0374370A (ja) 1989-08-16 1991-03-28 Terumo Corp ピラジン誘導体およびこれを含有する血小板凝集抑制剤または抗炎症剤
JP2597917B2 (ja) * 1990-04-26 1997-04-09 富士写真フイルム株式会社 新規な色素形成カプラー及びそれを用いたハロゲン化銀カラー写真感光材料
US5572248A (en) 1994-09-19 1996-11-05 Teleport Corporation Teleconferencing method and system for providing face-to-face, non-animated teleconference environment
WO1997043267A1 (en) 1996-05-11 1997-11-20 Kings College London Pyrazines
JP4026876B2 (ja) 1996-09-05 2007-12-26 日本食品化工株式会社 発光性シクロデキストリン誘導体及びその製造方法
JP2002241379A (ja) 1997-03-21 2002-08-28 Dainippon Pharmaceut Co Ltd ３−オキサジアゾリルキノキサリン誘導体
WO1999044609A1 (en) 1998-03-03 1999-09-10 Merck & Co., Inc. FUSED PIPERIDINE SUBSTITUTED ARYLSULFONAMIDES AS β3-AGONISTS
DE19826671A1 (de) 1998-06-16 1999-12-23 Hoechst Schering Agrevo Gmbh 1,3-Oxazolin- und 1,3-Thiazolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
JP3910365B2 (ja) 1998-07-16 2007-04-25 塩野義製薬株式会社 抗腫瘍活性を有するピリミジン誘導体
US7023913B1 (en) 2000-06-14 2006-04-04 Monroe David A Digital security multimedia sensor
DE60028936T2 (de) 1999-02-05 2007-01-11 Debiopharm S.A. Cyclosporin-derivate und verfahren zu deren herstellung
US6738073B2 (en) 1999-05-12 2004-05-18 Imove, Inc. Camera system with both a wide angle view and a high resolution view
US6479504B1 (en) 1999-06-16 2002-11-12 The University Of Iowa Research Foundation Antagonism of immunostimulatory CpG-oligonucleotides by 4-aminoquinolines and other weak bases
US7015954B1 (en) 1999-08-09 2006-03-21 Fuji Xerox Co., Ltd. Automatic video system using multiple cameras
US6660753B2 (en) * 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
ATE384704T1 (de) 1999-12-17 2008-02-15 Novartis Vaccines & Diagnostic Pyrazin-basierte hemmer der glycogen-synthase- kinase 3
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
US6849660B1 (en) 2000-08-01 2005-02-01 Isis Pharmaceuticals, Inc. Antimicrobial biaryl compounds
JP2002072370A (ja) 2000-08-29 2002-03-12 Fuji Photo Optical Co Ltd ペーパーマガジン及び写真焼付装置
JP2002072372A (ja) 2000-09-04 2002-03-12 Fuji Photo Film Co Ltd 画像形成用シート体の切断装置
US6829391B2 (en) 2000-09-08 2004-12-07 Siemens Corporate Research, Inc. Adaptive resolution system and method for providing efficient low bit rate transmission of image data for distributed applications
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
KR100884877B1 (ko) 2000-12-28 2009-02-23 다이이찌 세이야꾸 가부시기가이샤 Ｖｌａ-４ 저해제
US8085293B2 (en) 2001-03-14 2011-12-27 Koninklijke Philips Electronics N.V. Self adjusting stereo camera system
US6759657B2 (en) 2001-03-27 2004-07-06 Kabushiki Kaisha Toshiba Infrared sensor
WO2002080899A1 (fr) 2001-03-30 2002-10-17 Eisai Co., Ltd. Agent de traitement de maladie digestive
US6469002B1 (en) 2001-04-19 2002-10-22 Millennium Pharmaceuticals, Inc. Imidazolidine compounds
AU2002305450A1 (en) * 2001-05-08 2002-11-18 Yale University Proteomimetic compounds and methods
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102438D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
JP2003074370A (ja) 2001-09-05 2003-03-12 Suzuki Motor Corp エンジンのベルト保護装置
JP2005508321A (ja) 2001-09-26 2005-03-31 メルク　エンド　カムパニー　インコーポレーテッド 結晶形態のエルタペネムナトリウム
GB0124939D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
EP1446387B1 (en) 2001-11-21 2009-11-04 Pharmacia & Upjohn Company LLC Substituted aryl 1,4-pyrazine derivatives
US6992087B2 (en) * 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
US6693097B2 (en) 2001-11-30 2004-02-17 Synta Pharmaceuticals Corp. Pyrimidine compounds
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2003215087B2 (en) * 2002-02-06 2009-07-16 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of GSK-3
DK1485365T3 (da) 2002-03-13 2008-09-01 Janssen Pharmaceutica Nv Sulfonyl-derivater som nye inhibitorer af histandeacetylase
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
US7043079B2 (en) 2002-04-25 2006-05-09 Microsoft Corporation “Don't care” pixel interpolation
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
US7704995B2 (en) * 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
CA2484209C (en) 2002-05-03 2013-06-11 Exelixis, Inc. Protein kinase modulators and methods of use
IL164209A0 (en) 2002-05-31 2005-12-18 Eisai Co Ltd Pyrazole derivatives and pharmaceutical compositions containing the same
US7015227B2 (en) 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
AU2003245669A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
AU2003282679A1 (en) 2002-10-04 2004-05-04 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
US20040075741A1 (en) 2002-10-17 2004-04-22 Berkey Thomas F. Multiple camera image multiplexer
US7385626B2 (en) 2002-10-21 2008-06-10 Sarnoff Corporation Method and system for performing surveillance
US20040100560A1 (en) 2002-11-22 2004-05-27 Stavely Donald J. Tracking digital zoom in a digital video camera
SE0203754D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203752D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
JP4695588B2 (ja) 2003-02-26 2011-06-08 スージェン， インク． プロテインキナーゼ阻害剤としてのアミノヘテロアリール化合物
US7684624B2 (en) 2003-03-03 2010-03-23 Smart Technologies Ulc System and method for capturing images of a target area on which information is recorded
DE602004015429D1 (de) * 2003-03-11 2008-09-11 Pfizer Prod Inc Pyrazinverbindungen als inhibitoren des transforming growth factor (tgf)
US7459454B2 (en) * 2003-03-21 2008-12-02 Smithkline Beecham Corporation Aminopyrazine derivatives and compositions
AU2004224392A1 (en) 2003-03-24 2004-10-07 Merck & Co., Inc. Biaryl substituted 6-membered heterocyles as sodium channel blockers
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
GB2400514B (en) 2003-04-11 2006-07-26 Hewlett Packard Development Co Image capture method
AU2004240586A1 (en) 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists
WO2004103991A1 (fr) 2003-05-20 2004-12-02 'chemical Diversity Research Institute', Ltd. Piperidines 2-substituees, bibliotheque focalisee et composition pharmaceutique
US20050123902A1 (en) 2003-05-21 2005-06-09 President And Fellows Of Harvard College Human papillomavirus inhibitors
PE20050206A1 (es) 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
US7986339B2 (en) 2003-06-12 2011-07-26 Redflex Traffic Systems Pty Ltd Automated traffic violation monitoring and reporting system with combined video and still-image data
JP2005020227A (ja) 2003-06-25 2005-01-20 Pfu Ltd 画像圧縮装置
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
US7807696B2 (en) * 2003-10-07 2010-10-05 The Feinstein Institute For Medical Research Isoxazole and isothiazole compounds useful in the treatment of inflammation
US20050116968A1 (en) 2003-12-02 2005-06-02 John Barrus Multi-capability display
US20080194574A1 (en) 2003-12-16 2008-08-14 Axxima Pharmaceuticals Ag Pyrazine Derivatives As Effective Compounds Against Infectious Diseases
WO2005079802A1 (en) 2004-02-12 2005-09-01 Merck & Co., Inc. Bipyridyl amides as modulators of metabotropic glutamate receptor-5
US20050276765A1 (en) 2004-06-10 2005-12-15 Paul Nghiem Preventing skin damage
JP2008502687A (ja) 2004-06-14 2008-01-31 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
US7626021B2 (en) * 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7452993B2 (en) * 2004-07-27 2008-11-18 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
EP1786785B9 (en) 2004-08-26 2013-05-22 Pfizer Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
WO2006021886A1 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
US7730406B2 (en) 2004-10-20 2010-06-01 Hewlett-Packard Development Company, L.P. Image processing system and method
CN101084208A (zh) 2004-10-22 2007-12-05 詹森药业有限公司 作为c－fms激酶抑制剂的芳族酰胺
EP1828144A2 (en) 2004-11-12 2007-09-05 OSI Pharmaceuticals, Inc. Integrin antagonists useful as anticancer agents
JP2008520745A (ja) 2004-11-22 2008-06-19 バーテックス ファーマシューティカルズ インコーポレイテッド Ｒｈｏキナーゼの二環式阻害剤
JP4810669B2 (ja) 2004-11-25 2011-11-09 コニカミノルタホールディングス株式会社 有機エレクトロルミネッセンス素子、表示装置及び照明装置
GB0428235D0 (en) 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds
AU2005322338B2 (en) 2004-12-27 2011-06-09 Alcon, Inc. Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
US7622583B2 (en) * 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
GB0501999D0 (en) * 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
RU2007134259A (ru) 2005-02-16 2009-03-27 Шеринг Корпорейшн (US) Гетероциклические замещенные пиперазины, обладающие антагонистическим действием к cxcr3
CA2605738C (en) 2005-04-25 2013-10-01 Merck Patent Gesellschaft Mit Beschraenkter Haftung Novel azaheterocyclic compounds as kinase inhibitors
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
CA2610884A1 (en) 2005-06-09 2006-12-21 Merck & Co., Inc. Inhibitors of checkpoint kinases
AU2006275403A1 (en) 2005-08-02 2007-02-08 Lexicon Pharmaceuticals, Inc. 2-aminoaryl pyridines as protein kinases inhibitors
WO2007015632A1 (en) * 2005-08-04 2007-02-08 Cgk Co., Ltd. Atm and atr inhibitor
US7394926B2 (en) 2005-09-30 2008-07-01 Mitutoyo Corporation Magnified machine vision user interface
US7806604B2 (en) 2005-10-20 2010-10-05 Honeywell International Inc. Face detection and tracking in a wide field of view
AR056786A1 (es) 2005-11-10 2007-10-24 Smithkline Beecham Corp Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com
ATE452635T1 (de) 2005-12-01 2010-01-15 Hoffmann La Roche Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer
WO2007066805A1 (ja) 2005-12-09 2007-06-14 Meiji Seika Kaisha, Ltd. リンコマイシン誘導体およびこれを有効成分とする抗菌剤
KR20080080168A (ko) 2005-12-14 2008-09-02 이 아이 듀폰 디 네모아 앤드 캄파니 무척추 해충 방제용 이속사졸린
KR20080077652A (ko) 2005-12-22 2008-08-25 알콘 리서치, 리미티드 로 키나제-매개 질환 및 증상 치료용 (인다졸-5-일)피라진및 (1,3-디하이드로인돌-2-온)피라진
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
ITMI20060311A1 (it) 2006-02-21 2007-08-22 Btsr Int Spa Dispositivo perfezionato di alimentazione di filo o filatio ad una macchina tessile e metodo per attuare tale alimentazione
GB0603684D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
WO2007096764A2 (en) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
TW200800203A (en) 2006-03-08 2008-01-01 Astrazeneca Ab New use
CA2646701A1 (en) 2006-03-22 2007-10-04 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors for the treatment of proliferative disorders
US7574131B2 (en) 2006-03-29 2009-08-11 Sunvision Scientific Inc. Object detection system and method
JP2009532356A (ja) 2006-03-31 2009-09-10 シェーリング コーポレイション キナーゼ阻害物質
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
CA2655857C (en) * 2006-06-22 2014-12-02 Mallinckrodt Inc. Pyrazine derivatives with extended conjugation and uses thereof
EP2044051B1 (en) 2006-06-22 2010-01-27 BIOVITRUM AB (publ) Pyridine and pyrazine derivatives as mnk kinase inhibitors
EP1900727A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Aminopyridine derivatives as kinase inhibitors
RU2009115954A (ru) 2006-09-29 2010-11-10 Новартис АГ (CH) Пиразолопиримидины в качестве ингибиторов липидной киназы р13к
GB0619342D0 (en) 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
KR101107896B1 (ko) 2006-10-04 2012-01-25 에프. 호프만-라 로슈 아게 고 밀도 지단백질(ｈｄｌ)-콜레스테롤 상승제로서 3-피리딘카복스아마이드 및 2-피라진카복스아마이드 유도체
NZ576278A (en) 2006-10-19 2011-12-22 Signal Pharm Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
US8148361B2 (en) 2006-11-10 2012-04-03 Bristol-Myers Squibb Company Kinase inhibitors
US20080132698A1 (en) 2006-11-30 2008-06-05 University Of Ottawa Use of N-oxide compounds in coupling reactions
AR064348A1 (es) 2006-12-15 2009-04-01 Bayer Schering Pharma Ag 3-h-pirazolopiridinas y sales de estas, composiciones farmaceuticas que las comprenden, metodos para prepararlas y sus usos
CA2672438A1 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
MX2009008531A (es) 2007-02-16 2009-08-26 Amgen Inc Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
MX2009009304A (es) 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
JP2008260691A (ja) 2007-04-10 2008-10-30 Bayer Cropscience Ag 殺虫性アリールイソオキサゾリン誘導体
NZ580241A (en) 2007-04-10 2011-02-25 Bayer Cropscience Ag Insecticidal aryl isoxazoline derivatives
JP2010526823A (ja) 2007-05-10 2010-08-05 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのキノキサリン誘導体
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
UY31137A1 (es) 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
JP2009027904A (ja) 2007-06-19 2009-02-05 Hitachi Ltd 回転電機
EP2012409A2 (en) 2007-06-19 2009-01-07 Hitachi, Ltd. Rotating electrical machine
EP2157090A4 (en) 2007-06-21 2011-09-07 Taisho Pharmaceutical Co Ltd PYRAZINAMIDVERBINDUNG
EP2170306A1 (en) * 2007-06-26 2010-04-07 Lexicon Pharmaceuticals, Inc. Methods of treating serotonin-mediated diseases and disorders
EP2170339B1 (en) 2007-06-27 2014-10-15 Merck Sharp & Dohme Corp. Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors
GB0713259D0 (en) * 2007-07-09 2007-08-15 Astrazeneca Ab Pyrazine derivatives 954
KR20150118197A (ko) 2007-07-19 2015-10-21 하. 룬트벡 아크티에 셀스카브 5-원 헤테로시클릭 아미드 및 관련 화합물
BRPI0814441A2 (pt) 2007-07-19 2015-07-14 Schering Corp Compostos de amida heterocíclica como inibidores de proteína cinase
WO2009016460A2 (en) 2007-08-01 2009-02-05 Pfizer Inc. Pyrazole compounds and their use as raf inhibitors
WO2009024825A1 (en) 2007-08-21 2009-02-26 Astrazeneca Ab 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors
EP2203436A1 (en) 2007-09-17 2010-07-07 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
ATE523508T1 (de) * 2007-10-25 2011-09-15 Astrazeneca Ab Für die behandlung von zellproliferativen erkrankungen geeignete pyridin- und pyrazinderivate
JP2011511005A (ja) 2008-02-04 2011-04-07 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド ２−アミノピリジン系キナーゼ阻害薬
EP2250172B1 (en) * 2008-02-25 2011-08-31 F. Hoffmann-La Roche AG Pyrrolopyrazine kinase inhibitors
EP2247593B1 (en) * 2008-02-25 2011-08-10 F. Hoffmann-La Roche AG Pyrrolopyrazine kinase inhibitors
CN101939324B (zh) * 2008-02-25 2014-10-15 霍夫曼-拉罗奇有限公司 吡咯并吡嗪激酶抑制剂
EP2247595B1 (en) * 2008-02-25 2011-07-20 F. Hoffmann-La Roche AG Pyrrolopyrazine kinase inhibitors
TW200940537A (en) 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
US20110003859A1 (en) 2008-02-29 2011-01-06 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
US8110576B2 (en) * 2008-06-10 2012-02-07 Plexxikon Inc. Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
GB0814364D0 (en) 2008-08-05 2008-09-10 Eisai London Res Lab Ltd Diazaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase
CA2731368C (en) 2008-08-06 2013-05-14 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
AU2009279944B2 (en) 2008-08-06 2014-09-11 Medivation Technologies Llc Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
JP2010077286A (ja) 2008-09-26 2010-04-08 Aica Kogyo Co Ltd シリコーン樹脂組成物および粘着フィルム
WO2010048131A1 (en) 2008-10-21 2010-04-29 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors
KR20170015566A (ko) 2008-11-10 2017-02-08 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 화합물
EP3037421A3 (en) 2008-11-25 2016-11-30 University Of Rochester Mlk inhibitors and methods of use
CA2744507A1 (en) 2008-12-05 2010-06-10 F.Hoffmann-La Roche Ag Pyrrolopyrazinyl urea kinase inhibitors
KR101958632B1 (ko) * 2008-12-19 2019-03-15 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 피라진 유도체
WO2010075200A1 (en) 2008-12-22 2010-07-01 Array Biopharma Inc. 7-phenoxychroman carboxylic acid derivatives
UY32351A (es) 2008-12-22 2010-07-30 Astrazeneca Ab Compuestos de pirimidinil indol para uso como inhibidores de atr
MX2011006332A (es) * 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
RU2529860C2 (ru) 2009-01-30 2014-10-10 Тояма Кемикал Ко., Лтд. Производное n-ацилантраниловой кислоты или его соль
JP5353279B2 (ja) 2009-02-06 2013-11-27 Ｊｎｃ株式会社 セレンテラミド又はその類縁体の製造方法
BRPI1008020A2 (pt) * 2009-02-11 2016-03-15 Sunovion Pharmaceuticals Inc antagonistas e agonistas inversos h3 da histamina e métodos de uso dos mesmos
CN101537007A (zh) 2009-03-18 2009-09-23 中国医学科学院血液病医院（血液学研究所） N-(噻吩-2)吡唑并[1,5-a]嘧啶-3-甲酰胺类化合物在制备抗恶性肿瘤药物方面的应用
EP2411007A4 (en) * 2009-03-27 2012-12-05 Uab Research Foundation MODULATION OF IRES-MEDIATED TRANSLATION
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
KR101325828B1 (ko) 2009-07-13 2013-11-05 비덱스 에이/에스 뇌파를 탐지하도록 적응된 보청기 및 보청기 적응 방법
CN102471345A (zh) 2009-07-15 2012-05-23 雅培制药有限公司 激酶的吡咯并吡嗪抑制剂
IN2012DN00548A (hr) 2009-08-07 2015-06-12 Dow Agrosciences Llc
JP2011042639A (ja) 2009-08-24 2011-03-03 Kowa Co ビフェニルピラジン化合物及びこれを有効成分として含有するエリスロポエチン産生促進剤
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
DE102009043260A1 (de) 2009-09-28 2011-04-28 Merck Patent Gmbh Pyridinyl-imidazolonderivate
DK2485731T3 (en) 2009-10-06 2016-08-22 Millennium Pharm Inc Heterocyclic compounds that are useful as PDK1 INHIBITORS
AU2010319398B2 (en) 2009-11-13 2014-06-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer
PT2526090E (pt) 2010-01-18 2015-11-30 Medicines For Malaria Venture Mmv Novos agentes antimaláricos
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
AU2011236510A1 (en) 2010-04-08 2012-10-11 Zoetis Llc Substituted 3,5- di phenyl - isoxazoline derivatives as insecticides and acaricides
US20130030237A1 (en) 2010-04-15 2013-01-31 Charles Theuer Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
US8916593B2 (en) 2010-05-04 2014-12-23 Pfizer Inc. Alkoxy-substituted 2-aminopyridines as ALK inhibitors
JP2013529200A (ja) 2010-05-12 2013-07-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
WO2011143425A2 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US9096584B2 (en) * 2010-05-12 2015-08-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2011143426A1 (en) * 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2011143419A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Pyrazines useful as inhibitors of atr kinase
US8969356B2 (en) * 2010-05-12 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
MX2012013378A (es) 2010-05-20 2013-01-24 Hoffmann La Roche Derivados de pirrolo [2, 3-b] pirazina-7-carboxamida y sus uso como inhibidores de cinasa janus (jak) y cinasa tirosina del brazo (syk).
WO2011144584A1 (en) 2010-05-20 2011-11-24 F. Hoffmann-La Roche Ag Pyrrolopyrazine derivatives as syk and jak inhibitors
EP2585468A1 (en) * 2010-06-23 2013-05-01 Vertex Pharmaceuticals Incorporated Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
CN102311396B (zh) * 2010-07-05 2015-01-07 暨南大学 一种吡嗪类衍生物和其制备方法及在制药中的应用
EP2407478A1 (en) 2010-07-14 2012-01-18 GENETADI Biotech, S.L. New cyclotetrapeptides with pro-angiogenic properties
JP5782238B2 (ja) 2010-07-30 2015-09-24 ルネサスエレクトロニクス株式会社 電圧検出回路及びその制御方法
US8962623B2 (en) 2011-03-04 2015-02-24 Locus Pharmaceuticals, Inc. Aminopyrazine compounds
MX2013009953A (es) 2011-03-04 2013-09-26 Lexicon Pharmaceuticals Inc Inhibidores de cinasa de mst1 y metodos de su uso.
WO2012138938A1 (en) 2011-04-05 2012-10-11 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of tra kinase
AU2012255792A1 (en) 2011-05-17 2013-11-07 Principia Biopharma Inc. Azaindole derivatives as tyrosine kinase inhibitors
EP2723747A1 (en) * 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
US8822469B2 (en) * 2011-06-22 2014-09-02 Vertex Pharmaceuticals Incorporated Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase
JP2014517079A (ja) * 2011-06-22 2014-07-17 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
HUE046429T2 (hu) * 2011-09-30 2020-03-30 Vertex Pharma ATR kináz inhibítoraként használható vegyületek elõállítására szolgáló eljárás
IN2014CN02501A (hr) 2011-09-30 2015-06-26 Vertex Pharma
WO2013049720A1 (en) * 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN103958507A (zh) 2011-09-30 2014-07-30 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物
US8765751B2 (en) * 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8841337B2 (en) * 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071094A1 (en) * 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013071093A1 (en) * 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
US8846917B2 (en) * 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8841449B2 (en) * 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2015515478A (ja) 2012-04-05 2015-05-28 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物及びそれらの併用療法
CN103373996A (zh) 2012-04-20 2013-10-30 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的二并环衍生物
WO2014055756A1 (en) 2012-10-04 2014-04-10 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
US8912198B2 (en) 2012-10-16 2014-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
LT3418281T (lt) 2012-12-07 2021-01-11 Vertex Pharmaceuticals Inc. Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
JP6096005B2 (ja) 2013-02-26 2017-03-15 リンテック株式会社 シート剥離装置および剥離方法
CN105934435B (zh) 2013-12-06 2019-02-22 沃泰克斯药物股份有限公司 用作atr激酶抑制剂的化合物，其制备，及其放射性标记的衍生物
MX2016015874A (es) 2014-06-05 2017-03-27 Vertex Pharma Derivados radiomarcadores de un compuesto de 2-amino-6-fluoro-n-[5 -fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo.
ES2733847T3 (es) 2014-06-17 2019-12-03 Vertex Pharma Método para tratar cáncer usando una combinación de inhibidores de CHK1 y ATR

Also Published As

Publication number Publication date
HK1259148A1 (zh) 2019-11-29
US20180170922A1 (en) 2018-06-21
US10961232B2 (en) 2021-03-30
IL213613A0 (en) 2011-07-31
RU2011129761A (ru) 2013-05-20
US20150051187A1 (en) 2015-02-19
CA2747252C (en) 2018-09-18
DK3354650T3 (da) 2022-05-30
NO2376485T3 (hr) 2018-05-05
CN106496209A (zh) 2017-03-15
IL260158A (en) 2018-07-31
BRPI0924084A2 (pt) 2020-11-10
JP2016030756A (ja) 2016-03-07
KR101958632B1 (ko) 2019-03-15
LT3354650T (lt) 2022-06-27
EP3354650B1 (en) 2022-02-16
TW201028404A (en) 2010-08-01
CN102300862A (zh) 2011-12-28
US9365557B2 (en) 2016-06-14
MX2011006503A (es) 2011-09-06
US20100222318A1 (en) 2010-09-02
HRP20180385T1 (hr) 2018-04-06
LT2376485T (lt) 2018-03-26
CY1120002T1 (el) 2018-12-12
SI2376485T1 (en) 2018-04-30
TW201708213A (zh) 2017-03-01
DK2376485T3 (en) 2018-03-12
TWI543979B (zh) 2016-08-01
AU2016222396B2 (en) 2018-04-05
IL260158B (en) 2020-10-29
US10479784B2 (en) 2019-11-19
PL2376485T3 (pl) 2018-05-30
JP6212527B2 (ja) 2017-10-11
AR074822A1 (es) 2011-02-16
HUE036068T2 (hu) 2018-06-28
SG10201607592PA (en) 2016-11-29
KR101745331B1 (ko) 2017-06-09
EP4059932A1 (en) 2022-09-21
AU2016222396A1 (en) 2016-10-13
AU2018201363A1 (en) 2018-03-15
ES2663222T3 (es) 2018-04-11
CN102300862B (zh) 2016-11-23
CN106518856A (zh) 2017-03-22
US9701674B2 (en) 2017-07-11
AU2009327357A1 (en) 2011-07-28
KR20150003924A (ko) 2015-01-09
NZ593969A (en) 2013-11-29
BRPI0924084B1 (pt) 2021-12-21
CN106496209B (zh) 2020-06-30
IL213613A (en) 2015-01-29
JP5753093B2 (ja) 2015-07-22
IL236602A0 (en) 2015-02-26
TWI478918B (zh) 2015-04-01
CA3013000A1 (en) 2010-06-24
KR101755216B1 (ko) 2017-07-07
US20160311809A1 (en) 2016-10-27
JP2012512906A (ja) 2012-06-07
RU2604066C2 (ru) 2016-12-10
PL3354650T3 (pl) 2022-06-13
PT2376485T (pt) 2018-03-12
SI3354650T1 (sl) 2022-06-30
AU2009327357C1 (en) 2017-02-02
RU2016141566A3 (hr) 2020-02-17
PT3354650T (pt) 2022-06-20
ZA201104498B (en) 2012-10-31
AU2018201363C1 (en) 2020-06-18
IL236602B (en) 2018-07-31
JP5894643B2 (ja) 2016-03-30
EP2376485A1 (en) 2011-10-19
CA3013000C (en) 2022-12-13
KR20170081739A (ko) 2017-07-12
CA2747252A1 (en) 2010-06-24
CN106518856B (zh) 2020-04-28
EP2376485B1 (en) 2017-12-06
US20150031661A1 (en) 2015-01-29
RU2016141566A (ru) 2018-12-20
US20230030414A1 (en) 2023-02-02
WO2010071837A1 (en) 2010-06-24
US20190047995A1 (en) 2019-02-14
US8841308B2 (en) 2014-09-23
ES2921576T3 (es) 2022-08-29
KR20110096158A (ko) 2011-08-29
RS56995B1 (sr) 2018-05-31
TW201520210A (zh) 2015-06-01
TWI643854B (zh) 2018-12-11
SG172248A1 (en) 2011-07-28
JP2019194250A (ja) 2019-11-07
JP2018009010A (ja) 2018-01-18
CN106496210A (zh) 2017-03-15
JP2015024996A (ja) 2015-02-05
JP6577537B2 (ja) 2019-09-18
AU2018201363B2 (en) 2020-02-20
EP3354650A1 (en) 2018-08-01
CN106496210B (zh) 2020-06-09
AU2009327357B2 (en) 2016-06-16

Similar Documents

Publication Publication Date Title
HRP20220581T1 (hr) Spojevi korisni kao inhibitori atr kinaze
HRP20191375T1 (hr) Postupak liječenja raka upotrebom kombinacije chk1 i atr inhibitora
IL263262A (en) Atr kinase suppressant compounds, preparations containing them, their uses and methods for their preparation
HRP20171915T1 (hr) Spojevi korisni kao inhibitori atr kinaze i kombinirane terapije koje ih koriste
RU2012153675A (ru) Соединения, пригодные в качестве ингибиторов atr киназы
JP2013529643A5 (hr)
JP2013529199A5 (hr)
JP2013526540A5 (hr)
JP2012508260A5 (hr)
JP2013526538A5 (hr)
JP2013529200A5 (hr)
JP2014510151A5 (hr)
RU2011123647A (ru) Соединения, полезные в качестве ингибиторов atr киназы
JP2012512906A5 (hr)
JP2016512815A5 (hr)
CN108771681B (zh) 作为dna-pk抑制剂的化合物及其氘化衍生物的共晶
JP2015515478A5 (hr)
JP2013526539A5 (hr)
JP2018529713A5 (hr)
JP2016501244A5 (hr)
MX2013011450A (es) Compuestos de aminopirazina utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
EP2723747A1 (en) Compounds useful as inhibitors of atr kinase
CN111093660A (zh) 用于治疗癌症的组合疗法
CN110730660A (zh) Nrf和HIF活化剂/HDAC抑制剂和使用其的治疗方法
KR20170077160A (ko) 신규한 항암제로서의 치환 ２,４ 디아미노-퀴놀린